longevity
(81)
GOQii puts a human behind the numbers
A fitness tracker can count your steps. GOQii built a business around the person who asks why you stopped walking.
Modern Age raised $33 million. Then it needed a second life.
A New York clinic put blood tests, hormone care and Botox under one roof. Its closure and revival reveal the awkward business of selling a healthier future.
Assured Allies wants your insurer to pay for your independence
A coach, a safer home, a little more long-term care coverage. Assured Allies is building a business around the things that can happen before an insurance claim.
Life Biosciences Put Its Aging Theory in One Eye
The Boston biotech began with the immense ambition of treating aging itself. Its first human test is far narrower: can a gene therapy safely coax damaged optic-nerve cells toward a younger state?
The Second Blood Test Is the Point
Superpower sells 150-plus biomarkers, an AI-assisted plan and a second look at your blood. The interesting product is not the test. It is the feedback loop after it.
Thermal knows when science needs a story
A biotech PR firm put Scribe in the news one day before its co-founder won a Nobel Prize. The timing was a gamble. The preparation tells you more.
Globalive sold WIND for C$1.6 billion. Then it kept building.
Anthony Lacavera’s investment company turned a bruising telecom adventure into a business-building practice. Its next tests run from a Canadian bank to a mobile network in Bermuda.
Onto Health Bet $28 Million That Fertility Care Should Start Before the Panic
Most fertility businesses sell a treatment after something goes wrong. Onto Health is trying to sell clarity earlier - then use clinics, software and a $20 million Series A to carry patients through what comes next.
Vytal Health Bet Patients Would Pay to Be Heard - Then Built a $300-a-Month Alternative to the 10-Minute Visit
The Milwaukee telehealth practice asks patients to pay outside insurance for time, continuity and deeper testing. Its early obstacle was convincing people that a video visit could still feel human; its sharper 2026 answer is a two-tier membership with unusually clear boundaries.
Restore Turned a Bad Cryotherapy Visit Into a 200-Studio Wellness Machine
The founders thought athletes would fill the cryo chamber. They were wrong - and that mistake revealed a much larger market for convenient, repeatable wellness under one roof.
Longevity Science Left the Clinic. Lifespanning Put It in a Shopping Cart.
A Miami media company spent two decades inside biohacking's inner circle. Now it grades 1,000+ longevity products against a 72-point rubric - and only sells the ones that survive.
ConnectedLife Wants Your Wearable to Notice Trouble Before You Do
The Dubai-headquartered health platform is trying to turn the daily exhaust of modern life - sleep, steps, stress, blood pressure and more - into an early-warning system people and clinicians can actually use.
The Life Insurer That Would Rather You Stay Alive
At 164, John Hancock is recasting the oldest bargain in insurance: instead of waiting to pay after death, it rewards customers for living better now. The experiment links life insurance to wearables, cancer screening, longevity research and a growing stack of health technology.
Aktivo Labs
Aktivo Labs is a Singapore-based digital health-science company that turns everyday smartphone and wearable data into a proprietary digital biomarker, the Aktivo Score, a 1-99 measure of an individual's risk for chronic disease. It sells its platform to life and health insurers, reinsurers and employers, helping them run evidence-based wellness programs and understand population health risk. Founded in 2017, the company raised a US$10M Series A led by Mitsui & Co. in 2022 and operates across Asia-Pacific with expansion into the US, Europe and Japan.
Ultrahuman
Ultrahuman is a Bengaluru-founded health-technology company building a subscription-free wearable and diagnostics ecosystem centered on its Ring AIR and Ring PRO smart rings. Beyond the ring, the company sells a continuous glucose monitor (M1), a home environmental sensor (Ultrahuman Home) and a blood-biomarker service (Blood Vision), stitching them into a single app that turns sleep, movement, metabolic and recovery data into personalized nudges. Founded in 2019 by Mohit Kumar and Vatsal Singhal, it is now the second-largest smart-ring maker by units sold and is expanding US manufacturing to challenge market leader Oura.
Wei-Wu He
Wei-Wu He is a scientist, inventor, entrepreneur and investor who serves as Executive Chairman and CEO of Human Longevity, Inc., the San Francisco Bay Area precision-health company that pairs whole-genome sequencing with advanced imaging and blood analytics to catch age-related disease early. Trained as a molecular biologist at Baylor College of Medicine with an MBA from Wharton, he was among the first scientists at Human Genome Sciences before building OriGene Technologies into a major research-tools business. Over three decades he has founded or funded dozens of biotech companies through his venture fund Emerging Technology Partners, and he now channels that experience into the science of extending healthy human lifespan.
Function Health
Function Health is an Austin-based membership platform that gives consumers direct access to 100-plus lab tests, optional full-body MRI scans, and AI-generated insights for a flat annual fee. Founded in 2021 and led by CEO Jonathan Swerdlin with physician co-founder Mark Hyman, the company sells a data-first, preventive approach to healthcare aimed at helping members catch problems early and track their biology over time. After a $298M Series B in November 2025 at a $2.5B valuation, Function has become one of the fastest-growing consumer health companies in the US.
GlycanAge
GlycanAge is a UK-registered, Croatian-founded longevity biotech that measures biological age by analyzing glycans - sugar molecules attached to immune-system antibodies. Built on roughly two decades of glycobiology research led by Professor Gordan Lauc, the company turns a finger-prick blood sample into a report on how fast a person is aging at the molecular level, plus a specialist consultation to guide lifestyle changes. It sells directly to consumers and is expanding its glycan biomarkers into hospitals and preventive-care systems.
HERVolution Therapeutics
HERVolution Therapeutics is a Copenhagen-based biotechnology company developing immunotherapies that target human endogenous retroviruses (HERVs) - dormant remnants of ancient viruses embedded in human DNA that can reactivate with age and disease. Formerly named InProTher, the company has engineered a proprietary platform that redesigns these 'dark genome' antigens to break immune tolerance, making them visible to the immune system for the first time. Its off-the-shelf vector-based pipeline, led by IPT-001, aims to treat cancer, metabolic disease, and other diseases of aging.
Paratus Sciences
Paratus Sciences is a biotechnology company decoding the extreme biology of bats to discover first-in-class medicines. Bats live long, tolerate viruses, resist cancer, control inflammation and thrive on high-sugar diets - traits they evolved over roughly 65 million years. Paratus integrates cell biology, comparative genomics and informatics to translate these adaptations into drug targets for inflammatory and cardiometabolic diseases. Launched in 2023 with a $100M Series A and dual sites in New York and Singapore, its lead program PS-1001 is a first-in-class pan-inflammasome inhibitor.
PranaX
PranaX is a Houston-based regenerative medicine biotechnology company developing stem cell-derived exosome products to counter aging, inflammation, and tissue damage. Built on exosome technology exclusively licensed from The University of Texas MD Anderson Cancer Center, PranaX operates an FDA-registered cGMP facility at the Levit Green life science campus and is bringing to market a physician-directed exosome wellness supplement (ExoWELL) and a personal exosome banking service (ExoSTORE). The company closed an oversubscribed $17M Series A in early 2026.
IM8 (David Beckham & Danny Yeung's health drink startup)
IM8 is a premium longevity supplement brand co-founded by soccer icon David Beckham and serial entrepreneur Danny Yeung, operating as a consumer-health subsidiary of Nasdaq-listed Prenetics. In July 2026, IM8 secured $1 billion in growth financing from General Catalyst's Customer Value Fund (CVF), a non-dilutive facility that funds up to 70% of customer-acquisition spend in exchange for a capped share of cohort revenue rather than equity. Launched in December 2024, IM8 became the fastest-growing premium supplement brand on record, hitting roughly $100 million in annualized revenue within eleven months, and the capital is meant to pour fuel on marketing while ownership stays undiluted.
DexaFit
DexaFit is a health-testing company that turns a quick, low-radiation full-body DXA scan into a broad picture of a person's health - body composition, bone density, visceral fat and metabolic markers. Its AI arm, DexaFit Dx, layers machine learning on top of those same scans to screen for major chronic diseases such as coronary artery disease and type 2 diabetes, aiming to catch them early and non-invasively. Founded in Chicago in 2011 and now operating dozens of centers, DexaFit pairs in-person testing with an app that translates results into longevity scores, disease-risk estimates and trackable goals.
EMAD MOSTAQUE: AI Will RUN Our Countries Soon! We Aren't Ready!
In a wide-ranging interview on the Beyond Tomorrow podcast, Stability AI founder Emad Mostaque argues that within 30-40 years every country will be run by AI, that democracy is in its final decade or two, and that most digital jobs will be economically irrelevant within roughly a thousand days. He puts his personal probability of catastrophe (P-doom) at 50%, warns of intelligence being rationed by a duopoly of powerful labs, and lays out a counter-vision: sovereign, collectively owned 'national champion' AI utilities that give every citizen access to intelligence and a share of the robot fleet. Along the way he explores AI personhood, brain-computer interfaces, longevity escape velocity, quantum computing, and whether we should push a button to eliminate all human suffering.
Fullpower-AI
Fullpower-AI is a Santa Cruz, California science-and-technology company that builds real-time, contactless AI biosensing for sleep, remote patient monitoring, and longevity. Founded in 2005 by camera-phone pioneer Philippe Kahn and Sonia Lee, it operates the Sleeptracker-AI platform and the KOA Large Action Model, powering more than 300,000 Tempur-Pedic smartbeds and over 1.5 million connected devices across 60+ countries, backed by 135+ patents and ISO 27001 certification.
Human Longevity, Inc.
Human Longevity, Inc. is a San Diego- and South San Francisco-based genomics and precision-health company founded in 2013 by genome-sequencing pioneer J. Craig Venter, Peter Diamandis, and Robert Hariri. It pairs clinical-grade whole genome sequencing with whole-body MRI, hundreds of blood biomarkers, and AI analytics - delivered through its Health Nucleus platform - to detect cancer, cardiovascular disease, and other age-related conditions before symptoms appear. After a decade building one of the world's largest longitudinal genotype-phenotype datasets, the company in 2026 launched a $599 clinical-grade whole genome report and spun out Human Life Foundation Models, Inc. to build large-scale AI foundation models for longevity science.
InsideTracker
InsideTracker is a Cambridge, Massachusetts personalized health and wellness company (legally Segterra, Inc.) that turns your blood, DNA, and wearable data into a science-backed action plan. Founded in 2009 by MIT-trained scientist Dr. Gil Blander, the platform analyzes dozens of blood biomarkers, estimates your biological 'InnerAge,' and recommends specific foods, supplements, and lifestyle changes to optimize performance, healthspan, and longevity. It has become a favorite of athletes and quantified-self enthusiasts and integrates directly with Garmin, Fitbit, Oura, and Apple devices.
OneSkin
OneSkin is a San Francisco biotech and direct-to-consumer skincare company founded by four Brazilian women scientists who set out to slow skin aging at the molecular level. Its flagship OS-01 peptide - identified from a library of 900+ candidates using computational screening and tested on lab-grown human skin models - targets senescent 'zombie' cells that drive wrinkles, thinning and loss of firmness. The company sells topical 'supplements' for the face, eyes, body and sun protection, and frames skin not as a cosmetic surface but as the body's largest organ and a lever on overall healthspan.
Nikolina Lauc
Nikolina Lauc is co-founder and CEO of GlycanAge, a UK-based longevity diagnostics company built on two decades of glycobiology research from her father's laboratory in Zagreb. A serial entrepreneur since 18, she runs a business that translates a blood-based glycan test into a biological age readout, and she has become one of the more visible operators pushing preventive-health testing into the consumer market.
Rony Sellam
Rony Sellam is the CEO of InsideTracker, a Cambridge, Massachusetts based personalized-health company that uses blood biomarkers, DNA and lifestyle data to give consumers actionable recommendations for extending healthspan. A former Deloitte consultant from France by way of Geneva and a longtime healthcare IT executive, he has run InsideTracker for over a decade and helped push the company past 100,000 members and into partnerships with Oura and Fitness SF.